Needham Reiterates Buy Rating on Revolution Medicines, Keeps $275 Target
Needham reiterated its Buy rating and $275 price target on Revolution Medicines. The target implies 42.1% upside from the October 14 close of $193.52.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.